Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: Multivariate regression analysis of 20 genes

Clinical Genetics

Volumn 57, Issue 3, 2000, Pages 178-196

  Comings, David E ^a   Gade Andavolu, Radhika ^a   Gonzalez, Nancy ^a   Wu, Shijuan ^a   Muhleman, Donn ^a   Blake, Hezekiah ^a   Dietz, George ^a   Saucier, Gerard ^b   MacMurray, James P ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF OREGON   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Conduct disorder; Ggenes; Heterosis; Multifactorial; Oppositional defiant disorder; Polygenic; Psychiatric

Indexed keywords

DOPAMINE; NORADRENALIN; SEROTONIN;

ADRENERGIC SYSTEM; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HETEROSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEROTONINERGIC SYSTEM;

ADOLESCENT; ADULT; ALLELES; ANALYSIS OF VARIANCE; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CHILD; DOPAMINE; FEMALE; GENES, DOMINANT; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MODELS, GENETIC; NOREPINEPHRINE; REGRESSION ANALYSIS; SEROTONIN; TOURETTE SYNDROME; X CHROMOSOME;

EID: 0034108482     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2000.570304.x     Document Type: Article

References (122)

1. Stevenson J. Evidence for a genetic etiology in hyperactivity. Behav Genet 1992: 22: 337-344.
2. Stevenson J, Pennington BF, Gilger JW et al. Hyperactivity and spelling disability: testing for shared genetic aetiology. J Child Psychol Psychiatry 1993: 34: 1137-1152.
3. Sherman DK, Iacono WG, McGue MK. Attention-deficit hyperactivity disorder dimensions: a twin study of inattention and impulsivity-hyperactivity. J Am Acad Child Adolesc Psychiatry 1997: 36: 745-753.
4. Sherman DK, McGue MK, Iacono WG. Twin concordance for attention deficit hyperactivity disorder: a comparison of teacher's and mother's reports. Am J Psychiatry 1997: 154: 532-535.
5. Gillis JJ, Gigler JW, Pennington BF, Defries JC. Attention deficit disorder in reading-disabled twins: evidence for a genetic etiology. J Abnorm Child Psychol 1992: 20: 343-348.
6. Hudziak JJ, Heah A, Reich W et al. Latent class and genetic annalysis of DSM-IV attention-deficit, hyperactivity disorder. Am J Med Gen (Neuropsychol Genet) 1997: 74: 567-568.
7. Comings DE, Comings B, Muhleman D, Dietz G. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. J Am Med Assn 1991: 266: 1793-1800.
8. Comings DE, Wu H, Chiu C, Ring RH, Dietz G, Muhleman D. Polygenic inheritance of Tourette syndrome, stuttering, ADHD, conduct and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes-DRD2, DβH and DAT1. Am J Med Gen (Neuropsych Genet) 1996: 67: 264-288.
9. Lahoste GJ, Swanson JM, Wigal SB et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996: 1: 121-124.
10. Swanson JM, Sunohara GA, Kennedy JL et al. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family based approach. Mol Psychiatry 1998: 3: 38-41.
11. Rowe DC, Stever C, Giedinghagen LN et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry 1998: 3: 419-426.
12. Faraone SV, Biederman J, Weiffenbach B et al. The dopamine D4 gene 7-repeat allel is associated with ADHD in families ascertained through ADHD adults. Am J Med Gen (Neuropsychol Genet) 1998: 81: 458.
13. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptability loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 1999: 4: 192-196.
14. Cook EH, Stein MA, Krasowski MD et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995: 56: 993-998.
15. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997: 2: 311-313.
16. Waldman ID, Rowe DC, Abramowitz A et al. Association of the dopamine transporter gene (DAT1) and attention deficit hyperactivity disorder. Am J Hum Genet 1996: 59: A25.
17. Comings DE, Gade-Andavolu R, Gonzalez N, Blake H, Wu S, MacMurray JP. Additive effect of three noradrenergic genes (ADRA2A, ADRA2C, DBH) on attention deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin Genet 1999: 55: 160-172.
18. Comings DE et al. Association of the angrogen receptor gene (AR) with ADHD and conduct disorder. Neuroreport 1999: 10: 1589-1592.
19. Lau EK, Castellanos FX, Tayebi N et al. Association studies do not show an increased frequency of the 7-fold repeat form of the dopamine 4 receptor polymorphisms in children with attention deficit hyperactivity disorder (ADHD). Am J Hum Genet 1997: 61: A203.
20. Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence amoung relatives. Ann Hum Genet 1965: 29: 51-71.
21. Pastinen T, Perola M, Niini P et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infaction in the Finnish population. Hum Mol Genet 1998: 7: 1453-1462.
22. A receptor β3 subunit genes and alcoholism. Psychiatry Res 1998: 81: 133-147.
23. Comings DE. Polygenetic inheritance of psychiatric disorders. In: Blum K, Noble EP, Sparks RS, Sheridan PJ, eds. Handbook of Psychiatric Genetics. Boca Raton, FL: CRC Press, 1996.
24. Comings DE. SNPs and polygenic disorders: a less gloomy view. Mol Psychiatry 1999: 4: 314-316.
25. Comings DE. Letter to the Editor: Tourette syndrome a polygenic disorders. CNS Spectrums 1999: 4: 14-15.
26. McGee R, Williams S, Silva PH. Behavioral and developmental characteristics of aggressive, hyperactive and aggressive-hyperactive boys. J Am Acad Child Psychiatry 1989: 23: 270-279.
27. Stewart MA, Cummings C, Singer S, Deblois CS. The overlap between hyperactive and unsocialized aggressive children. J Child Psychol Psychiatry 1981: 22: 35-45.
28. Faraone SV, Biederman J, Keenan K, Tsuang MT. Separation of DSM-III attention deficit disorder and conduct disorder - evidence from a family-genetic study of American child psychiatric patients. Psychol Med 1991: 21: 109-121.
29. Comings DE, Comings BG. Tourette's syndrome and attention deficit disorder with hyperactivity: are they genetically related. J Am Acad Child Psychiatry 1984: 23: 138-146.
30. Comings DE, Comings BG. A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems. Am J Hum Genet 1987: 41: 701-741.
31. Comings DE, Comings BG. Comorbid behavioral disorders. In: Kurlan R, ed. Handbook of Tourette's Syndrome and Related Tic and Behavioral Disorders. New York, NY: Marcel-Decker, 1993.
32. Comings DE. ADHD with Tourette syndrome or Tic disorders. In: Brown TE, ed. Attention Deficit Disorders and Comorbidities in Children, Adolescents and Adults. Washington, DC: Am. Psychiat. Press, 1998.
33. Comings DE. Tourette syndrome: a hereditary neuropsychiatric spectrum disorder. Ann Clin Psychiatry 1995: 6: 235-247.
34. Robins LN, Helzer J, Croughan J, Ratclif KS. National Institute of Health diagnostic interview schedule. Arch Gen Psychiatry 1981: 38: 381-389.
35. American Psychiatric Association. Diagnostic and Statistical Manual of the American Psychiatric Association IV. Washington, DC: American Psychiatric Association, 1994.
36. Comings DE. The role of genetic factors in conduct disorder based on studies of Tourette syndrome and ADHD probands and their relatives. J Dev Behav Pediatr 1995: 16: 142-157.
37. Comings DE. Genetic factors in depression based on studies of Tourette syndrome and attention deficit hyperactivity disorder probands and relatives. Am J Med Gen (Neuropsychol Genet) 1995: 60: 111-121.
38. Kawanishi Y, Harada S, Tachikawa H, Okubo T, Shiraishi H. Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am J Med Gen (Neuropsychol Genet) 1998: 81: 434-439.
39. Bergen A, Wang CY, Nakhai B, Nielsen D, Goldman D. Mass screening of rare 5HT1A variants using ECL detection. Am J Hum Genet 1994: 55: A180.
40. Warren JT, Peacock ML, Fink JK. An Rsa I polymorphism in the human serotonin receptor gene (HTR1A): detection by DGGE and RFLP analysis. Hum Mol Genet 1990: 1: 778.
41. 1A receptor gene. Psychiatry Genet 1999: 9: 105-106.
42. WU S AND COMINGS DE (2000) Two single nucleotide polymorphisms in the promoter region of the human phenylethanolamine N-methyltransferase PNMT gene. Psychiatry Genet (in press)
43. Seeman P, Madras BK. Anti-hyperactivity medication: methylpheidate and amphetamine. Mol Psychiatry 1998: 3: 386-396.
44. Giros B, Es SR, Wrightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking dopamine transporter. Nature 1996: 379: 606-612.
45. Blum K, Wood RC, Sheridan PJ, Chen T, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive, addictive and compulsive disorders. Pharmacogenetics 1995: 5: 121-141.
46. Sherrington R, Baljinder BS, Attwood J et al. A highly polymorphic microsatellite for the human dopamine (D5) receptor (DRD5) shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics 1994: 18: 423-425.
47. Bauer LO, Hasselbrock VM. Subtypes of familiy history and conduct disorder: effects on P300 during the Stroop test. Neuropsychophamralcology 1999: 21: 51-62.
48. Smalley SL, Bailey JN, Palmer CG et al. Evidence that the dopamine D4 receptor is a susceptability gene in attention deficit hyperactivity diosrder. Mol Psychiatry 1998: 3: 427-430.
49. Comings DE, Gonzalez N, Wu S et al. Studies of the 48 bp repeat of the DRD4 gene in impulsive-addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Gen (Neuropsychol Genet) 1999: 88: 358-368.
50. Daly G, Hawi Z, Fitzgerald M, Gill M. Attention deficit hyperactivity disorder association with the dopamine transporter (DAT1) but not with the dopamine D4 receptor (DRD4). Am J Med Gen (Neuropsychol Genet) 1998: 81: 501.
51. Asherson P, Virdee V, Curran S et al. Association of DSM-IV attention deficit hyperactivity disorder (ADHD) and monoamaine pathway genes. Am J Med Gen (Neuropsychol Genet) 1998: 81: 549.
52. Weinberg WA, Harper CR. Vigilance and its disorders. Neurol Clin 1993: 11: 59-78.
53. Mefford IN, Potter WZ. A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Med Hypot 1989: 29: 33-42.
54. Aston-Jones G, Foote SL, Bloom FE. Anatomy and physiology oflocus coeruleus neurons: Functional implications. In: Ziegler MG, ed. Frontiers of Clinical Neuroscience, Vol. 2. Baltimore, MD: Williams and Williams, 1984.
55. Carli M, Robbins TW, Evenden JL, Everitt BJ. Effect of lesions to ascending noradrenergic neurons on performance of 5-choice serial reaction task in rats: implication for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983: 9: 361-380.
56. Usher M, Cohen JD, Rajkowski J, Kubiak P, Aston-Jones G. The role of locus coeruleus in the regulation of cognitive performance. Science 1999: 283: 544-549.
57. Antelman SM, Caggiula AR. Norepinephrine-dopamine interactions and behavior. Science 1977: 195: 646-653.
58. 2-noradrenergic mechanism to prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996: 53: 448-455.
59. Arnsten AFT. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997: 11: 151-162.
60. Arnsten AFT, Goldman-Rakic PS. Reversal of stress-induced delayed response deficits in rhesus monkeys by clonidine and naloxone. Soc Neurosci Abstr 1986: 12: 1464.
61. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985: 24: 617-629.
62. Leckman JF, Cohen DJ, Detlor J, Young JG, Harcherik D, Shaywitz BA. Clonidine in the treatment of Tourette syndrome: a review of data. Adv Neurol 1982: 35: 391-401.
63. Aston-Jones G. Neuromodulation and cognitive function: recent studies of noradrenergic neurons in behaving monkeys. In: Uylings HNBM et al.. eds. Cognition, Emotion and Autonomic Responses. Amsterdam (in press): Elsevier, 2000.
64. Klinteberg BA, Magnusson D. Aggressiveness and hyperactive behavior as related to adrenaline excretion. Special Issue: personality and aggression. Eur J Personal 1989: 3: 81-93.
65. Pliszka SR, Maas JW, Rogeness GA, Baker J. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1994: 33: 1165-1173.
66. Comings DE, MacMurray JM. Molecular heterosis: implications for complex inheritance. Am J Hum Genet 1997: 61: A196.
67. Comings DE. Molecular heterosis as the explanation for the controversy about the effect of the DRD2 gene on dopamine D2 receptor density. Mol Psychiatry 1999: 4: 213-215.
68. Karp RW. Genetic studies in alcohol research. Am J Med Gen (Neuropsychol Genet) 1994: 54: 304-308.
69. Comings DE. The clinical and molecular genetics of ADHD and Tourette syndrome: two related polygenic disorders. In: Wassertein J. Wolf L, LeFever FF, eds. Adult Attention Deficit Disorder: Brain Mechanisms and Life Outcomes. New York. NY: NY Acad Sci, 2000.
70. Gade R, Muhleman D, MacMurray J, Comings DE. Correlation of length of VNTR alleles at the X-linked MAOA gene and phenotypic effect in Tourette syndrome and drug abuse. Mol Psychiatry 1998: 3: 50-60.
71. van Praag HM. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatry Scand Suppl 1998: 393: 81-88.
72. Moldin SO. The maddening hunt for madness genes. Nature Genet 1997: 17: 127-129.
73. Comings DE. Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene. Alcohol 1995: 16: 61-70.
74. Halperin JM, Newcorn, JH, Koda VH, Pick L, McKay KE, Knott P. Noradrenergic mechanisms in ADHD children with and without reading disabilities: a replication and extension. J Am Acad Child Adolesc Psychiatry 1997: 36: 1688-1696.
75. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996: 35: 264-272.
76. Hacia JG, Brody LC, Collins FS. Application of DNA chips for genomic analysis. Mol Psychiatry 1995: 3: 483-492.
77. Falconer DS. Introduction to Qualitative Genetics. 2nd Ed. New York, NY: Longman, 1981.
78. Lochlin JC. Genes and Environment in Personality Development. Newbury Park: Sage, 1992.
79. Lynch M, Walsh B. Genetics and Analysis of Quantitative Traits. Sunderland, MA: Sinaure Associates. Inc. 1998.
80. Cichon S, Nöthen MM, Erdman J, Propping P. Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1). Hum Mol Genet 1994: 3: 209.
81. Comings DE, Gade R, Wu S et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997: 2: 44-56.
82. Grandy DK, Litt M, Allen L et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989: 45: 778-785.
83. Jönsson E, Sedvall G, Brené S et al. Dopamine-related genes and their relationship to monamine metabolites in CSF. Biol Psychiatry 1996: 40: 1032-1043.
84. Lannfelt L, Sokoloff P, Martres M-P et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatry Genet 1992: 2: 249-256.
85. Crocq M-A, Mant R, Asherson P et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992: 29: 858-860.
86. Asherson P, Mant R, Holmans P et al. Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Mol Psychiatry 1996: 1: 125-132.
87. Comings DE, Muhleman D, Dietz G, Dino M, Legro R, Gade R. Association between Tourette's syndrome and homozygosity at the dopamine-D3 receptor gene. Lancet 1993: 341: 906.
88. Comings DE, Rosenthal RJ, Lesieur HR et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996: 6: 223-234.
89. Comings DE, Gonzalez N, Wu S et al. Association of the dopamine DRD3 receptor gene with cocaine dependence. Mol Psychiatry 1999: 4: 484-487.
90. Duaux E, Gorwood P, Griffon N et al. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 1998: 3: 333-336.
91. Lichter JB, Barr CL, Kennedy JL, Van Tol HHM, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor (DRD4) gene. Hum Mol Genet 1993: 2: 767-773.
92. Epstein RP, Novick O, Umunsky R et al. Dopamine D4 receptor (D4DR) exon III polymorphism asociated with the human personality trait of novelty seeking. Nat Genet 1996: 12: 78-80.
93. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996: 12: 81-84.
94. Grice DE, Leckman JF, Pauls DL et al. Linkage disequilibrium of an allele at the dopamine D4 receptor locus with Tourette's syndrome by TDT. Am J Hum Genet 1996: 59: 644-652.
95. Nicolini H, Cruz C, Camarena B, Ṕez F, Sidenberg D, De La Fuente JR. The 7-repeat variant of the DRD4 gene is increased in obsessive-compulsive behavior with ties. Biol Psychiatry 1997: 42: 26S.
96. Perez de Castro I, Ibanez A, Torres P, Saiz-Ruiz J, Fernandez-Piqueras J. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997: 7: 345-348.
97. Vanyokov MM, Moss HB, Gioio AE, Hughes HB, Kaplan BB, Tarter RE. An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. Behav Genet 1998: 28: 75-81.
98. Vandenbergh DJ, Persico AM, Hawkins AL et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992: 14: 1866 1868.
99. Vandenbergh DJ, Persico AM, Uhl GR. A human dopamine transporter eDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic Taq 1 RFLPs. Mol Brain Res 1992: 15: 161-166.
100. Waldman ID, Mohr JH, Abramowitz A et al. The relation between childhood antisocial behavior and the dopamine transporter gene (DAT1): mediation via hyperactivty-impulsivity. Am J Med Gen (Neuropsychol Genet) 1998: 81: 459.
101. 2A promoter polymorphism -1438G/A and obsessive-compulsive disorder. Am J Med Gen (Neuropsychol Genet) 1998: 81: 502.
102. Collier DA, Stöber G, Li T et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptability to affective disorders. Mol Psychiatry 1996: 1: 453-460.
103. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996: 66: 2621-2624.
104. Little KY, McLaughlin DP, Zhang L et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998: 155: 207-213.
105. Lesen K-P, Bengel D, Helis A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996: 274: 1527-1531.
106. Lappalainen J, Dean M, Charbonneau L, Virkkunen M, Linnoila M, Goldman D. Mapping the serotonin 5-HT1Dβ autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Gen (Neuropsychol Genet) 1995: 60: 157-161.
107. Lappalainen J, Long JC, Eggert M et al. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in two populations. Arch Gen Psychiatry 1998: 55: 989-994.
108. Ozaki N, Lappalainen J, Dean M, Virkkunen M, Linnoila M, Goldman D. Mapping of the serotonin 5-HT1Dα autoreceptor gene (5-HTR1Dα) on chromosome 1 using a silent polymorphism in the coding region. Am J Med Genet 1995: 60: 162-164.
109. Williams J, Spurlock G, McGuffin P et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 1996: 347: 1294-1296.
110. Arranz M, Collier D, Sodhi M et al. Association between clozapine response and allelic variantion in 5-HT2A receptor gene. Lancet 1995: 346: 281-282.
111. Inayama Y, Yoneda H, Sakai T et al. Positive association between DNA sequence variant in the serolonin 2A receptor gene and schizophrenia. Am J Med Gen (Neuropsychol Genet) 1996: 67: 103-105.
112. Comings DE, Muhleman D, Dietz G, Sherman M, Forest G. Sequence of human tryptophan 2.3-dioxygenase: presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat. Genomics 1995: 29: 390-396.
113. Comings DE, Muhelman D, Gade R et al. Exon and intron mutations in the human tryptophan 2.3-dioxygenase gene and their potential association with Tourette syndrome, substance abuse and other psychiatric disorders. Pharmacogenetics 1996: 6: 307-318.
114. Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydrolylase polymorphism. Arch Gen Psychiatry 1994: 51: 34-58.
115. Nielsen DA, Virhunen M, Lappalainen J el al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998: 55: 593-602.
116. Wu S, Muhleman D, Comings DE. PCR amplification of the Taq 1 B1 B2 polymorphism at intron 5 of the dopamine β-hydroxylase gene. Psychiatry Genet 1997: 7: 39-40.
117. Wei J, Ramchand CN, Hemmings GP. Possible control of dopamine β-hydroxylase via a codominant mechanism associated with polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum Genet 1997: 99: 52-55.
118. Lario S, Calls J, Cases A, Orila J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997: 51: 129-130.
119. Charara N, Kuntzelmann G, Munro J, Kerwin RW, Loetscher E. Structural polymorphism in the a2B adnrenoreceptor: no association with schizophrenia or clozapine responsiveness. Am J Med Gen (Neuropsychol Genet) 1998: 81: 510.
120. Riess O, Weber B, Hayden MR. CA)n-dinucleotide repeat polymorphism at the locus for the alpha2C adrenergic receptor (ADRA2C) on 4q16. Hum Mol Genet 1992: 1: 452.
121. Stöber G, Pörtgen P, Bönisch H, Beckman H, Propping P, Nöthen MM. Systematic screening for mutations in the coding region of the noradrenaline transporter gene. Psychiatry Genet 1995: 5: S98.
122. Lachman HM, Morrow B, Shpritzen R et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996: 67: 468-472.